Expression of melanoma-associated antigens in melanoma cell cultures

Experimental Dermatology

Volumn 14, Issue 7, 2005, Pages 491-497

  Urosevic, Mirjana ^a   Braun, Bettina ^a   Willers, Jörg ^a,b   Burg, Günter ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

Flow cytometry; gp100; MAGE; Melan A MART 1; Tyrosinase

Indexed keywords

ALPHA INTERFERON; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MONOPHENOL MONOOXYGENASE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL POPULATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; MELANOMA CELL; PREPUCE; PROTEIN EXPRESSION; TIME; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE I, RECOMBINANT; KINETICS; MALE; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 21244493998     PISSN: 09066705     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0906-6705.2005.00305.x     Document Type: Article

References (29)

1. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996: 183: 725-729.
2. Dunn G P, Bruce A T, Ikeda H, Old L J, Schreiber R D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002: 3: 991-998.
3. Parmiani G, Castelli C, Rivoltini L et al. Immunotherapy of melanoma. Semin Cancer Biol 2003: 13: 391-400.
4. Takahashi K, Shichijo S, Noguchi M, Hirohata M, Itoh K. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis. Cancer Res 1995: 55: 3478-3482.
5. Zendman A J, Ruiter D J, Van Muijen G N. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003: 194: 272-288.
6. van Duinen S G, Ruiter D J, Broecker E B et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988: 48: 1019-1025.
7. Kamarashev J, Ferrone S, Seifert B et al. TAP1 downregulation in primary melanoma lesions: an independent marker of poor prognosis. Int J Cancer 2001: 95: 23-28.
8. Jager E, Ringhoffer M, Altmannsberger M et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997: 71: 142-147.
9. Maeurer M J, Gollin S M, Martin D et al. Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J Clin Invest 1996: 98: 1633-1641.
10. Moller P, Hammerling G J. The role of surface HLA-A,B,C molecules in tumour immunity. Cancer Surv 1992: 13: 101-127.
11. Rivoltini L, Barracchini K C, Viggiano V et al. Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes. Cancer Res 1995: 55: 3149-3157.
12. Dummer R, Yue F Y, Pavlovic J et al. Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10. Br J Cancer 1998: 77: 1413-1419.
13. Geertsen R C, Hofbauer G F, Yue F Y, Manolio S, Burg G, Dummer R. Higher frequency of selective losses of HLA-A and -B allospecificities in metastasis than in primary melanoma lesions. J Invest Dermatol 1998: 111: 497-502.
14. Murer K, Urosevic M, Willers J et al. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients. Melanoma Res 2004: 14: 257-262.
15. Chapman P B. Immunotherapy of melanoma. Cancer Chemother Biol Response Modif 2002: 20: 371-383.
16. Hofbauer G F, Schaefer C, Noppen C et al. MAGE-3 immunoreactivity in formalin-fixed, paraffin-embedded primary and metastatic melanoma: frequency and distribution. Am J Pathol 1997: 151: 1549-1553.
17. Eichmuller S, Usener D, Jochim A, Schadendorf D. mRNA expression of tumor-associated antigens in melanoma tissues and cell lines. Exp Dermatol 2002: 11: 292-301.
18. Cormier J N, Hijazi Y M, Abati A et al. Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 1998: 75: 517-524.
19. Cormier J N, Salgaller M L, Prevette T et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997: 3: 37-44.
20. Lohmann C M, Iversen K, Jungbluth A A, Berwick M, Busam K J. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma. Am J Surg Pathol 2002: 26: 1351-1357.
21. Ross D T, Scherf U, Eisen M B et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000: 24: 227-235.
22. Rao U N, Jones M W, Finkelstein S D. Genotypic analysis of primary and metastatic cutaneous melanoma. Cancer Genet Cytogenet 2003: 140: 37-44.
23. Dunn G P, Old L J, Schreiber R D. The three Es of cancer immunoediting. Annu Rev Immunol 2004: 22: 329-360.
24. Kirkwood J M, Manola J, Ibrahim J, Sondak V, Ernstoff M S, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004: 10: 1670-1677.
25. Murray J L, Stuckey S E, Pillow J K, Rosenblum M G, Gutterman J U. Differential in vitro effects of recombinant alpha-interferon and recombinant gamma-interferon alone or in combination on the expression of melanoma-associated surface antigens. J Biol Response Mod 1988: 7: 152-161.
26. Giacomini P, Fraioli R, Nistico P et al. Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon. Int J Cancer 1990: 46: 539-545.
27. Krasagakis K, Garbe C, Kruger S, Orfanos C E. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or-gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 1991: 97: 364-372.
28. Hofbauer G F, Geertsen R, Laine E, Burg G, Dummer R. Impact of interferons on the expression of melanoma-associated antigens in melanoma short-term cell cultures. Melanoma Res 2001: 11: 213-218.
29. Rimoldi D, Salvi S, Schultz-Thater E, Spagnoli G C, Cerottini J C. Anti-MAGE-3 antibody 57B and anti-MAGE-1 antibody 6C1 can be used to study different proteins of the MAGE-A family. Int J Cancer 2000: 86: 749-751.